StockpollyBeta
Get App
Popularity #4,616
OKYO · NASDAQ · Biotechnology

OKYO Pharma (OKYO)

Develops urcosimod eye drops for neuropathic corneal pain and anterior-segment eye diseases.

$1.34
vs last close−0.01 (−1.11%)

In millions of USD, except per-share figures

In millionsQ2 FY21Sep 2020Q4 FY21Mar 2021Q2 FY22Sep 2021Q4 FY22Mar 2022Q2 FY23Oct 2022Q4 FY23Mar 2023Q2 FY24Oct 2023Q4 FY24Mar 2024Q2 FY25Oct 2024Q4 FY25Mar 2025Q2 FY26Sep 2025Q4 FY26Mar 2026
Cost of revenue00000—0000——
Gross profit00000—000000
13076—903436
Research & development00023—502002
Selling, general & administrative130530401435
Operating income−1−30−7−6—−90−3−4−3−6
00000—00−1000
Interest income00000—000000
Interest expense000000001000
Other non-operating income000000000000
Income before tax−1−30−7−6—−90−4−4−3−6
Income tax expense000−10—0—−1−2—0
Net income from continuing operations−1−30−6−6—−9—−3−2−3−6
Other adjustments000000000000
Net income−1−30−6−6—−9—−3−2−3−6
EPS, basic−$0.11−$0.27−$0.00−$0.36−$0.00−$0.00−$0.00−$0.00−$0.08−$0.04−$0.07−$0.17
EPS, diluted−$0.11−$0.27−$0.00−$0.36−$0.00−$0.00−$0.00−$0.00−$0.08−$0.04−$0.07−$0.17
Weighted average shares, basic101114162223263334393737
Weighted average shares, diluted101114162223263334393737
EBITDA−1−30−7−6—−9—−3−4—−6
Depreciation & amortization00000—0—00——
EBIT−1−30−7−6—−90−3−4−3−6